Logo video2dn
  • Сохранить видео с ютуба
  • Категории
    • Музыка
    • Кино и Анимация
    • Автомобили
    • Животные
    • Спорт
    • Путешествия
    • Игры
    • Люди и Блоги
    • Юмор
    • Развлечения
    • Новости и Политика
    • Howto и Стиль
    • Diy своими руками
    • Образование
    • Наука и Технологии
    • Некоммерческие Организации
  • О сайте

Скачать или смотреть Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental..

  • Labroots
  • 2018-03-02
  • 574
Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental..
NeurodevelopmentalColleen NiswenderPharmacologyMetabotropic GlutamateRett syndrome (RTT)mGlu7Drug DiscoveryLabRootsVirtual EventWebinar
  • ok logo

Скачать Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental.. бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental.. или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

  • Информация по загрузке:

Cкачать музыку Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental.. бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental..

Presented At:
Drug Discovery 2018

Presented By:
Colleen Niswender, PhD - Professor of Pharmacology, Director of Molecular Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery

Speaker Biography:
Colleen Niswender is a Professor of Pharmacology at Vanderbilt University and the Director of Molecular Pharmacology for the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). During her graduate training and initial postdoctoral studies, she worked to elucidate the molecular mechanisms regulating the RNA editing of AMPA and serotonin receptors. She then pursued postdoctoral studies focused on the genetic regulation of Protein Kinase A using recombinant mice at the University of Washington. Her work at the VCNDD involves assay development, high throughput screening and characterization of novel G protein-coupled receptor allosteric ligands both in vitro and in vivo. She has been involved in multiple small molecule discovery projects to search for and characterize novel allosteric modulators of various metabotropic glutamate (mGlu) and muscarinic receptors. This work has resulted in the progression of an M1 muscarinic receptor positive allosteric modulator, discovered at Vanderbilt, through Investigational New Drug Application studies and into clinical development for the treatment of cognitive deficits in Alzheimer's disease and schizophrenia. During the past five years, Dr. Niswender has established a new research program focused on the therapeutic potential of mGlu and muscarinic receptor allosteric modulators for the treatment of various neurodevelopmental disorders, including Rett syndrome, MECP2 Duplication syndrome, and Neurofibromatosis Type 1.

Webinar:
Allosteric Modulation of Metabotropic Glutamate Receptors for the Treatment of Neurodevelopmental Disorders

Webinar Abstract:
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the Methyl CpG Binding Protein 2 (MECP2) gene. In mouse models of RTT, deficits in long-term potentiation (LTP) at Schaffer collateral (SC)-CA1 synapses in the hippocampus, as well as impairments in learning and memory. The metabotropic glutamate receptor 7 (mGlu7) is the primary mGlu receptor expressed presynaptically at SC-CA1 synapses in adult mice, and is required for the induction of LTP. By examining autopsy samples from human RTT patients, we have found an approximately 70 percent reduction in mGlu7 protein expression in both cortex and cerebellum. mGlu7 levels are also reduced in RTT model mice and positive allosteric modulation of mGlu7 activity restores LTP and improves contextual fear learning and social phenotypes. Furthermore, mGlu7 potentiation decreases apneas in RTT model mice, suggesting that mGlu7 may represent a therapeutic target for multiple aspects of the RTT phenotype.
While RTT is caused by loss-of-function mutations in MECP2, MECP2 Duplication syndrome (MDS) is another severe neurodevelopmental disorder resulting from overexpression of the MeCP2 protein. Mouse models of RTT and MDS show opposing changes in presynaptic activity at SC-CA1 synapses, and we hypothesized that genetic reduction of mGlu7 or an mGlu7 negative allosteric modulator (NAM) might correct deficits in MDS-model mice. Surprisingly, cognitive and anxiety phenotypes found in MDS animals were not impacted by reducing mGlu7 expression or by administration of an mGlu7 NAM. In contrast, a PAM unexpectedly corrected these deficits, suggesting that shared underlying circuitry changes between RTT and MDS may explain these findings. Finally, this presentation will touch upon primary GRM7 mutations and SNPs that are now being correlated with severe neurodevelopmental disorders in clinical populations.

Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (Link to Event Microsite)
2. Watch the webinar on YouTube above or on the LabRoots Website (Link to Event Microsite)
3. Click Here to get your PACE (Expiration date –February 21, 2020 12:00 PM)– http://www.labroots.com/credit/pace-c...
4. Click here to get your CME credits (Expiration date – 3 months from event) – https://www.surveymonkey.com/r/WXSK62V

LabRoots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc

Комментарии

Информация по комментариям в разработке

Похожие видео

  • О нас
  • Контакты
  • Отказ от ответственности - Disclaimer
  • Условия использования сайта - TOS
  • Политика конфиденциальности

video2dn Copyright © 2023 - 2025

Контакты для правообладателей [email protected]